SUBSCRIBE
SUBSCRIBE
News   Business

Johnson & Johnson Signs Potential $500 Million Drug Deal with Astex Therapeutics

June 9, 2008 | 
1 min read
LONDON, June 9 (Reuters) - Britain's Astex Therapeutics has signed a cancer drug research deal with Johnson & Johnson potentially worth more than $500 million in milestone payments, it said on Monday.
Alliances Mergers & acquisitions Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
July 16, 2025
 · 
1 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Ventus “Recalibrates” to Support Mid-Stage Trials
July 16, 2025
 · 
159 min read
 · 
BioSpace Editorial Staff
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
 · 
1 min read
 · 
Heather McKenzie
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis